Friday 16 October 2026
Export ADCT’s income statement to Excel — free account
ADC Therapeutics SA
ADCT Healthcare Biotechnology
ADC Therapeutics SA’s revenue for fiscal 2025 (year ended December 2025) was $81.4 million, up 14.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.17%, EPS grew 78.0%, free cash flow grew 51.0% and total debt rose 1.87%, each against the same quarter a year earlier.
1.41
0.08
−5.37%
Follow ADCT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 5 | 3 | 2 |
| 81.41% | 73.43% | 60.27% | 45.35% | ||
| (52.26%) | (44.22%) | (48.57%) | (32.25%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(74.16%) | (60.39%) | (65.50%) | (55.26%) | |
Average Days of Receivables |
111.22 | 130.63 | 143.12 | 128.58 | |
Free Cash Flow per Share |
(0.97) | (1.11) | (0.74) | (0.66) | |
Free Cash Flow |
(132.26) | (140.78) | (113.92) | (101.64) | |
Capital Expenditures |
(0.35) | 0.40 | 0.63 | 0.63 | |
| Other line items | |||||
Cash ROIC |
(118.34%) | (73.72%) | (87.43%) | (94.53%) | |
Accounts Receivable Turnover |
3.20 | 3.29 | 2.52 | 2.94 | |
Accounts Payable Turnover |
0.49 | 0.43 | 0.70 | 0.79 | |
Inventory Turnover |
0.32 | 1.80 | 0.66 | 0.78 | |
Average Days of Payables |
541.76 | 577.59 | 262.88 | 525.41 | |
Days of Inventory on Hand |
1,203.90 | 263.39 | 237.11 | 203.07 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
150.14% | 127.84% | 119.93% | 103.32% | |
Selling, General and Administrative Expense of Revenue |
105.53% | 98.25% | 103.60% | 107.22% | |
Share Based Compensation of Revenue |
10.43% | 8.49% | 8.75% | 12.14% | |
Interest Coverage |
(2.69) | (2.35) | (2.29) | (1.90) | |
Operating CF/Net income |
0.79 | 0.99 | 0.84 | 1.06 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | — | |
Capex/Depreciation |
(0.08) | 0.11 | 0.20 | 0.00 | |
Revenue per Share |
0.55 | 0.64 | 0.51 | 0.51 | |
Operating CF per Share |
(0.97) | (1.11) | (0.74) | (0.66) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | (0.01) | (0.01) |
Columns are period end dates